November 8, 2019: Novaliq GmbH

Novaliq and Jiangsu Hengrui Medicine announce a strategic collaboration in ophthalmology for the EyeSol®-based investigational products NOV03 and CyclASol® in China

Jiangsu Hengrui Medicine secures exclusive rights to develop, manufacture, and commercialize NOV03 and CyclASol® in China.
NOV03 (perfluorohexyloctane) is a first-in-class investigational drug with a novel mode of action to treat Dry Eye Disease (DED) associated with Meibomian gland dysfunction (MGD).
CyclASol® (0.1% cyclosporine A in EyeSol®) is an anti-inflammatory and immunomodulating investigational drug developed for the treatment of aqueous deficient DED.
Novaliq is eligible to receive upfront and milestone payments of up to $165 million plus royalties.

Novaliq GmbH, a pharmaceutical company focusing on first- and best-in-class ocular therapeutics, and Jiangsu Hengrui Medicine Co., Ltd. (SSE: 600276), a fully integrated biopharmaceutical company based in China, announce today the closing of an exclusive license agreement to develop, manufacture, and commercialize the innovative, water-free drugs NOV03 and CyclASol® for the treatment of dry eye disease in People’s Republic of China (including mainland China, Hong Kong, Macau and Taiwan).

Please read the whole article here

Novaliq GmbH

November 7, 2019: Apogenix AG

Strong Quality of Life Data for Apogenix’ Asunercept Published in Journal of Neuro-Oncology

Asunercept Plus Radiotherapy Significantly Prolongs Time to Deterioration of Quality of Life Compared to Radiotherapy Alone in Patients with Recurrent Glioblastoma

Apogenix, a biopharmaceutical company developing next generation immuno-oncology therapeutics, announced today that a new publication in Journal of Neuro-Oncology1 shows that in patients with recurrent glioblastoma, treatment with asunercept in combination with radiotherapy is associated with a statistically significant prolongation in time to deterioration of quality of life beyond progression of the disease compared to treatment with radiotherapy alone.

Please read the whole article here

Apogenix AG

November 6, 2019: AC Immune SA

AC Immune Hosts Key Opinion Leader Event: ‘Untangling’ Tau Pathology to Treat Alzheimer’s and Neurodegenerative Diseases

AC Immune SA, a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced highlights from its Key Opinion Leader (KOL) meeting focused on “untangling” Tau pathology as an important therapeutic and diagnostic target for Alzheimer’s disease (AD) and other neurodegenerative diseases, held in New York City today at 12pm ET. The archived webcast of the event can be viewed here.

Please read the whole article here

AC Immune SA

November 7, 2019: Heidelberg Pharma AG

Heidelberg Pharma Announces Participation at Various Conferences

Heidelberg Pharma AG today announced that they will participate at the following investor events and scientific conferences. Heidelberg Pharma is an oncology specialist and the first company to develop the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology, and to advance the biological mode of action of the toxin as a novel therapeutic principle.

Please read the whole article here

Heidelberg Pharma AG

November 4, 2019: Cosmo Pharmaceuticals NV

Cosmo’s Partner RedHill announces approval of Talicia® for the treatment of H. Pylori in adults in the USA

Cosmo Pharmaceuticals N.V. today informs that its partner RedHill Biopharma (NASDAQ: RDHL, Tel-Aviv Stock Exchange: RDHL) today announced that the U.S. Food and Drug Administration (FDA) has approved Talicia® (omeprazole magnesium1 10.3 mg, amoxicillin 250 mg and rifabutin 12.5 mg) delayed-release capsules for the treatment of Helicobacter pylori (H. pylori) infection in adults.

Please read the whole article here

Cosmo Pharmaceuticals NV

October 25, 2019: Heidelberg Pharma AG

Notice to Holders

of the convertible bonds issued by Heidelberg Pharma AG (ISIN DE000A2GSZA0 / WKN A11QVV)

Please read the whole article here

Heidelberg Pharma AG

October 24, 2019: AC Immune SA

AC Immune to Host Key Opinion Leader Event: ‘Untangling’ Tau Pathology to Treat Alzheimer’s and Neurodegenerative Diseases

AC Immune SA, a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced it will host a key opinion leader (KOL) meeting focused on pathological Tau protein as a therapeutic target and diagnostic biomarker for Alzheimer’s and other neurodegenerative diseases. The event will take place in New York City on Wednesday, November 6, 2019.

Please read the whole article here

AC Immune SA

October 24, 2019: CureVac AG

CureVac to Present CV8102 Data at SITC Conference

CureVac AG, a clinical stage biopharmaceutical company pioneering the field of mRNA-based drugs, today announced that it will participate in the Society for Immunotherapy of Cancer (SITC) conference 2019 in National Harbor, Maryland, from November 6-10. On Nov. 9, CureVac will present an update and preliminary biomarker data on the ongoing phase I dose escalation clinical trial with the RNA-based cancer therapy, CV8102, in patients with advanced solid tumors.

Please read the whole article here

CureVac AG

October 18, 2019: Cosmo Pharmaceuticals NV

Cosmo licenses Aemcolo™ for the USA to RedHill Biopharma and takes a 19.56% stake in the company

Cosmo Pharmaceuticals N.V. today announced that it has concluded a licensing agreement for Aemcolo™ for the USA and a simultaneous share subscription agreement with RedHill Biopharma (NASDAQ: RDHL, Tel-Aviv Stock Exchange: RDHL).

Please read the whole article here

Cosmo Pharmaceuticals NV

October 10, 2019: Apogenix AG

Apogenix to Present at Several Upcoming International Conferences

Apogenix, a biopharmaceutical company developing next generation immuno-oncology therapeutics, announced today that it will attend several upcoming international conferences. In two presentations, Apogenix will give updates on TNF superfamily receptor agonists HERA-CD40L and HERA-GITRL. The company will further present a poster on the therapeutic benefit of orphan drugs in oncology.

Please read the whole article here

Apogenix AG